Panzegrau Beata, Gordon Leonie, Goudy Glen H
Department of Radiology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
J Nucl Med Technol. 2005 Mar;33(1):28-30.
We retrospectively analyzed the safety, cost effectiveness, and patient acceptance of outpatient high-dose 131I treatment for thyroid cancer at our hospital since 1997, when the Nuclear Regulatory Commission began allowing high-dose outpatient therapy with radioiodine.
Forty-eight patients were treated as outpatients because their living conditions were acceptable and they were willing to comply with radiation safety guidelines. The homes of 3 patients were surveyed for contamination. The cost of outpatient treatment was compared with the cost of inpatient treatment. Patient acceptance was assessed by patient satisfaction surveys performed at the time of the posttherapy scan.
No levels of contamination above regulatory levels were found in patients' homes. The cost of outpatient treatment was favorable. All surveyed patients were pleased with the procedure.
If state and federal guidelines for releasing patients are followed, and if patients' living conditions are adequately assessed, outpatient treatment with high-dose 131I is safe and cost effective and improves patient satisfaction.
自1997年核管理委员会开始允许门诊使用高剂量放射性碘治疗以来，我们回顾性分析了我院门诊高剂量131I治疗甲状腺癌的安全性、成本效益和患者接受度。
48例患者接受门诊治疗，因为他们的生活条件允许且愿意遵守辐射安全指南。对3例患者的家中进行了污染调查。将门诊治疗费用与住院治疗费用进行比较。通过治疗后扫描时进行的患者满意度调查评估患者接受度。
在患者家中未发现高于监管水平的污染程度。门诊治疗费用较为可观。所有接受调查的患者对该治疗过程都很满意。
如果遵循州和联邦关于患者出院的指导方针，并且对患者的生活条件进行充分评估，那么门诊高剂量131I治疗是安全且具有成本效益的，并且能提高患者满意度。
